Winfried F. Pickl, MD, on Using a Novel Biomarker to Predict CAR-T Responses in DLBCL

By Cecilia Brown, Winfried F. Pickl, MD - Last Updated: March 9, 2023

Winfried F. Pickl, MD, of the Institute of Immunology, Medical University of Vienna, discusses using a novel biomarker to predict responses to chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma.

See part two of the interview on the future of the novel biomarker here.

What Is the Optimal Treatment Sequence for Relapsed or Refractory T-Cell Lymphoma?

Melissa BadamoT-Cell Lymphoma | April 3, 2025

Mark Sorial, PharmD, BCOP, shared the latest research from the Salvia Jain Lab's PETAL Consortium.

Urvi Shah, MD, Highlights the Significance and Limitations of Observational Nutritional Studies

Urvi A. Shah, MDMyeloma | March 27, 2025

Dr. Shah discusses the significance and limitations of two studies on dietary factors and risk of myeloma and MGUS.

Study Identifies Dietary Risk Factors for Myeloma

Francesca Castro, MS, RDN, CDNMyeloma | March 26, 2025

A plant-based diet is significantly associated with a reduced risk of multiple myeloma.

What Are the Dietary Risk Factors for MGUS?

Janine Joseph, MS, MBAMyeloma | March 24, 2025

A US population-based study investigated the associations between MGUS and various dietary patterns.

What Does the Future Hold for DLBCL Care? What Direction Should New Research Take?

Tara Graff, DO, MSAggressive B-Cell Lymphoma | March 10, 2025

The expert panel describes outstanding clinical research needs in DLBCL and what research underway they find exciting.

Winfried F. Pickl, MD, on Using a Novel Biomarker to Predict CAR-T Responses in DLBCL

Related Posts